{"id":124961,"date":"2025-03-14T00:00:00","date_gmt":"2025-03-14T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2025\/03\/14\/aad-maintenance-of-low-eczema-activity-seen-after-about-80-days-off-tapinarof\/"},"modified":"2025-03-18T15:10:29","modified_gmt":"2025-03-18T15:10:29","slug":"aad-maintenance-of-low-eczema-activity-seen-after-about-80-days-off-tapinarof","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2025\/03\/14\/aad-maintenance-of-low-eczema-activity-seen-after-about-80-days-off-tapinarof\/","title":{"rendered":"AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof"},"content":{"rendered":"<h3>\n<p>Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval<\/p>\n<\/h3>\n<p><b>By Elana Gotkine HealthDay Reporter<\/b><br \/>\n<b><\/b><\/p>\n<p>FRIDAY, March 14, 2025 (HealthDay News) &#8212; Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease activity after about 80 days off treatment, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida.<\/p>\n<p>David Rosmarin, M.D., of the Indiana University School of Medicine in Indianapolis, and colleagues conducted a 48-week open-label, long-term extension study (ADORING 3) evaluating tapinarof in 728 eligible adults and children aged 2 years or older with AD. Patients entering ADORING 3 with Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) \u22651 received tapinarof until vIGA-AD = 0 (completely clear skin). Those entering or achieving vIGA-AD = 0 discontinued tapinarof and were assessed for maintenance while off treatment. Those whose AD returned to vIGA-AD \u22652 were retreated until vIGA-AD = 0.<\/p>\n<p>The researchers found that at the end of the first treatment-free interval (mean, 79.8 days), 84.0 percent of patients had vIGA-AD = 2, a mean Eczema Area and Severity Index score of 3.4, and a mean weekly Peak Pruritus-Numerical Rating Scale score of 2.9. At the end of subsequent treatment-free intervals, similar low disease activity was seen. After about 80 consecutive days off treatment, a high proportion of patients demonstrated low disease activity, including itch.<\/p>\n<p>&#8220;These data reinforce the efficacy of Vtama cream in atopic dermatitis, including the durability of effect among patients in the study, including children as young as 2 years old,&#8221; Juan Camilo Arjona Ferreira, M.D., head of research and development and chief medical officer at Organon, said in a statement.<\/p>\n<p>The study was funded by Dermavant Sciences, which was acquired by Organon.<\/p>\n<p><a href=\"https:\/\/www.organon.com\/news\/new-analysis-of-organons-vtama-tapinarof-cream-1-phase-3-data-shows-atopic-dermatitis-disease-activity-remained-low-after-treatment-free-interval-in-adults-and-children-2-years-of-ag\/\">Press Release<\/a><\/p>\n<p><a href=\"https:\/\/www.aad.org\/member\/meetings-education\/am25\">More Information<\/a><\/p>\n<p><i><\/i><br \/>\n<i>Copyright &#169; 2025 <a href=\"https:\/\/consumer.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval<\/p>\n","protected":false},"author":6,"featured_media":125912,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-124961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/124961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=124961"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/124961\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/125912"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=124961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=124961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=124961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}